A Study of the Efficacy and Safety of Alectinib in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer

NCT03155009 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

44

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG: Alectinib

Sponsor

Hoffmann-La Roche